Abstract Capecitabine 1000 mg/m 2 bid 9 14 days every 21 days (14/21) has been reported to have similar efficacy but more favorable toxicity profile than the approved dosage of 1250 mg/m 2 . However, a dose-toxicity relationship of capecitabine in breast cancer patients has not been fully elucidated. We performed a systematic review and meta-analysis to compare a safety profile between capecitabine starting dose of 1000 and 1250 mg/m 2 bid. Studies were identified using PubMed, ASCO, and San Antonio Breast Cancer Symposium abstract databases through December 2015. Eligible trials included phase II/ III trials of capecitabine monotherapy at 1000 or 1250 mg/ m 2 bid (14/21) for breast cancer patients that reported adequate safety data for all (grade 1-4) or high (grade 3-4) grade hand foot syndrome (HFS), diarrhea, fatigue, nausea, vomiting, stomatitis, neutropenia, thrombocytopenia, or anemia, as well as dose reductions, treatment discontinuation or treatment-related deaths. The summary incidence was calculated using random-effects models. A total of 4833 patients from 34 trials were included. 1218 and 3615 patients were treated with capecitabine 1000 and 1250 mg/ m 2 bid, respectively. A significantly lower incidence of dose reduction (15.9 vs. 39.0 %; P = 0.007), high-grade HFS (12.0 vs. 19.0 %; P = 0.01), diarrhea (5.3 vs. 9.1 %; P = 0.01), and neutropenia (1.8 vs. 7.3 %; P \ 0.01), and all-grade neutropenia (5.8 vs. 25.4 %; P = 0.01) was seen in capecitabine 1000 mg/m 2 compared to 1250 mg/m 2 . Capecitabine monotherapy at 1000 mg/m 2 bid (14/21) has a clinically meaningful and significantly better toxicity profile compared to 1250 mg/m 2 bid (14/21).
Introduction
Capecitabine is an oral pro-drug that is converted to 5-fluorouracil (5-FU) via a three-step enzymatic process, the final step of which is mediated by thymidine phosphorylase. Given this enzyme is over expressed in tumor compared with normal tissue, 5-FU is preferentially generated within the tumor tissue, conferring relatively selective cytotoxicity to the tumor [1] . Capecitabine is one of the most active agents in metastatic breast cancer (MBC). The FDA has approved capecitabine monotherapy 1250 mg/m 2 twice daily (bid) on days 1-14 followed by a 7-day rest period (14/21) for MBC that is resistant to both paclitaxel and anthracyclines [2] . It has also been extensively studied in both pretreated and previously untreated MBC patients and demonstrated efficacy in response rate and progression-free survival (PFS) [3, 4] . However, 26-65 % of patients had their dose reduced by at least 20 % in these trials [5, 6] . The main treatment-limiting toxicities at this dosage were hand-and-foot syndrome (HFS; also called palmer-plantar erythrodysesthesia) and diarrhea. Based on this experience, a number of investigators have evaluated capecitabine at a lower starting dose (1000 mg/m 2 bid) and demonstrated similar efficacy to the approved dose and a more favorable side effect profile with an incidence of dose reduction, ranging from 16 to 34 % in phase II trials [7, 8] . However, there has been a substantial variation in the incidence of toxicities among clinical trials and there has been no systematic attempt to synthesize these data in order to define the overall risk of toxicities induced by the lower and standard dose capecitabine. Therefore, we conducted a systematic review and metaanalysis of available clinical trials to compare a safety profile between capecitabine starting dose of 1000 and 1250 mg/m 2 bid in breast cancer patients.
Methods

Data source
This analysis was performed in accordance with the preferred reporting items for systematic reviews and metaanalyses (PRISMA) statement [9] . We conducted an independent review of PubMed from January 1966 to December 2015. Searches were performed by using the keywords ''capecitabine'' and ''breast cancer'' and were limited to clinical trials. We searched abstracts and virtual meeting presentations utilizing the same search terms from the American society of clinical oncology (ASCO) conference and San Antonio breast cancer symposiums (SABCS) through December 2015 to identify relevant studies. An independent search of the web of science, Embase, and Cochrane electronic databases was also performed to ensure that no additional studies were overlooked. In cases of duplicate publications, only the most complete, recent, and updated report of the study was included.
Study selection
Clinical trials that met the following criteria were included: (1) phase II and III trials of capecitabine monotherapy at 1000 or 1250 mg/m 2 bid on day 1 through 14 every 3 weeks for breast cancer patients; and (2) reporting events or event rate and sample size for any all (grade 1-4) or high (grade 3-4) grade adverse events (AEs), individual, all or high grade AEs, dose reductions, treatment discontinuation or treatment-related deaths. We assessed nine individual AEs which were commonly reported in clinical trials. They included hand foot syndrome (HFS), diarrhea, fatigue, nausea, vomiting, stomatitis, neutropenia, anemia, and thrombocytopenia. We did not include trials of capecitabine combined with other agents. Independent reviewers (TFN and MS) screened reports that included the key terms by their titles and abstracts for relevance. Then, full texts of the relevant articles were retrieved to assess eligibility. The references of relevant reports were also reviewed manually.
Data extraction
Two investigators (TFN and MS) independently performed data extraction. The following information was recorded for each study: first author's name, year of publication, trial phase, age, disease stage, treatment setting, capecitabine dose, number of patients available for analysis, number of cycles of capecitabine, CTCAE version, and number of the following adverse events: any, all, or high grade AEs, individual, all or high grade AEs (HFS, diarrhea, fatigue, nausea, vomiting, stomatitis, neutropenia, anemia and thrombocytopenia), dose reductions, treatment discontinuation and treatment-related deaths. Any discrepancies between reviewers were resolved by consensus. The number of patients evaluable for toxicity was utilized as the number analyzed for each trial, unless this was not indicated in the publication, in which case, the number of patients enrolled was utilized. In selected clinical trials, the adverse events were recorded according to the CTCAE.
Statistical analysis
The principal summary measures were incidence and corresponding 95 % confidence intervals (CIs) of the following AEs: any, all, or high grade AEs, individual, all or high grade AEs (HFS, diarrhea, fatigue, nausea, vomiting, stomatitis, neutropenia, thrombocytopenia, and anemia), dose reductions, treatment discontinuation and treatmentrelated deaths. The proportion of patients with those adverse outcomes and 95 % CIs were derived from each trial. Statistical heterogeneity in results between trials included in the meta-analysis was examined using Cochrane's Q statistic, and inconsistency was quantified with I 2 statistic [100 % 9 (Q -df)/Q], which estimates the percentage of total variation across studies due to heterogeneity rather than chance [10] . The assumption of homogeneity was considered invalid for P values less than 0.10. We used a random-effects model to produce a pooled overall estimate for incidence of the adverse outcomes. Differences in the incidences between the two groups were assessed using Q statistics. We evaluated publication bias using funnel plots and with the Begg and Egger tests [11, 12] . A two-tailed P value of less than 0.05 was considered statistically significant. Statistical analyses were performed by using the comprehensive meta-analysis program (Version 2, Biostat, Englewood, NJ, USA). 
Results
Search results and population characteristics
Our search strategy yielded 391 potentially relevant publications. 360 citations were excluded. This large proportion of studies that had to be excluded from analyses consisted of reviews, observational studies, non-capecitabine trials, non-breast cancer trials and trials of capecitabine combined with other therapy This selection process and reasons for study exclusion are shown in a flow diagram ( Fig. 1) . We found additional reports identified through manual review of the references of included publications and ASCO and SABCS abstract database [7, 13, 14] . Thus, a total of 34 trials with 4833 patients were considered eligible for the meta-analysis, including 12 phase III trials and 22 phase II trials. 30 trials were in the locally advanced or MBC setting, two trials were in the neoadjuvant setting, and two trials were in the adjuvant setting (Table 1) . 1218 patients from 13 trials and 3615 patients from 23 trials were treated with capecitabine starting dose at 1000 and 1250 mg/m 2 bid, respectively. There were two trials which modified the capecitabine starting dose from 1250 to 1000 mg/m 2 bid. These trials reported toxicity outcomes according to the capecitabine starting dose [15, 16] . We did not include a trial which administered capecitabine 1250 mg/m 2 bid in patients B65 years and 1000 mg/m 2 bid in patients [65 years and did not report toxicity outcomes separately for the two dosing groups [17] . There were differences in the number of trials included for each endpoint because the study endpoints of interest were not consistently reported in all trials.
Comparison of toxicity profiles (toxicity profile)
Toxicity data for high grade HFS were available for 33 trials. The incidence of high-grade HFS in patients receiving capecitabine 1000 mg/m 2 bid and 1250 mg/m 2 bid was respectively 12.0 % (95 % CI 9.0-15.7 %) and 19.0 % (95 % CI 15.2-23.4 %) by using the random-effects model ( Table 2 ). The test for heterogeneity was significant in the lower (Q = 17.5; P = 0.06; I 2 = 42.9) and approved (Q = 149.0; P \ 0.001; I 2 = 85.9) dose groups. There was a significant decrease in the incidence of high grade HFS with the use of the lower dose compared with the standard dose (P = 0.01). High-grade diarrhea developed less frequently in patients treated with the lower dose of capecitabine than those treated with the approved dose (5.3 vs. 9.1 %; P = 0.011). There were fewer all-grade neutropenia events among patients treated with capecitabine 1000 mg/m 2 bid (5.8 %) than among patients treated with 1250 mg/m 2 bid (25.4 %). A lower incidence of high- bid (P = 0.007). The incidence of dose reduction with the lower and approved dose capecitabine was respectively 15.9 % (95 % CI 7.5-30.5 %) and 39.0 % (95 % CI 32.4-45.9 %). There was also a trend toward lower incidence of high-grade vomiting (P = 0.05) and high-grade anemia (P = 0.08) in the capecitabine 1000 mg/m 2 bid group compared with the 1250 mg/m 2 bid group. There was no significant difference in the incidence of treatment discontinuation and treatment-related deaths between the two groups.
Publication bias
We found no evidence of publication bias for incidence of any all-and high-grade AEs, all-and high grade HFS, fatigue, vomiting, and stomatitis and all-grade diarrhea, nausea and anemia and dose reductions, treatment discontinuation and treatment-related deaths. The Egger test suggested some evidence of publication bias (P \ 0.05) for incidence of all-and high-grade neutropenia and thrombocytopenia and high-grade diarrhea, nausea, and anemia. However, the Begg tests showed no evidence of bias for the incidence of these outcomes (P [ 0.05). This difference in the results obtained from the two methods may be due to a greater statistical power of the Egger test [44] .
Discussion
A goal of the current analysis was to systematically assess the overall risk of toxicities associated with the lower and standard dose capecitabine. Our meta-analysis of 34 clinical trials demonstrated a dose-toxicity relationship of capecitabine in breast cancer patients. A significantly lower incidence of dose reductions, high grade HFS, diarrhea, neutropenia and all-grade neutropenia was observed in capecitabine starting dose of 1000 mg/m 2 bid compared to 1250 mg/m 2 bid. These findings reinforce the results of the previous retrospective study performed by Hennessy et al. at M. D. Anderson Cancer Center [45] . In their study, 106 patients receiving capecitabine monotherapy who were evaluable for toxicity were grouped according to the starting dose of capecitabine: A = 1250 ± 5 % mg/m 2 bid (n = 51); B = 1125 ± 5 % mg/m 2 bid. (n = 16); C B 1000 ? 5 % mg/m 2 bid (n = 39). Although no statistical comparison was performed, the incidence of dose reduction (28 vs. 41 %), high grade HFS (20 vs. 33 %), and diarrhea (3 vs. 13 %) was numerically lower in the group C compared with group A. Overall it showed a trend to a better tolerability with the lower dose of capecitabine. In addition to the milder toxicity profile, clinical trials have shown that a lower starting capecitabine dose is comparable in efficacy to the approved dose despite the lack of a randomized trial comparing the two approaches. Ran- Because of the substantial heterogeneity in the trial settings including treatment intent (curative vs. palliative) and line of therapy, we did not perform a meta-analysis of the trials to compare the efficacy of capecitabine starting dose of 1250-1000 mg/m 2 bid. These data coupled with clinical experience and the palliative goal of treatment in MBC have led many clinicians to start their MBC patients on a lower starting dose of capecitabine than the 1000 mg/m 2 bid dose, whether as first-line treatment or later in the course of therapy. Ambros and colleagues commonly prescribe capecitabine in their MBC population at a fixed dose of 1000 mg bid for 14 of every 21 days within their single large breast-specific oncology group [47] . Given the lack of published data on this dose, they retrospectively analyzed data from 86 patients treated with this regimen (CAPE-L) regardless of the number of prior therapy lines. The median starting dose was 633.5 mg/m 2 (range: 303.4-965.3) bid, roughly 50 % of the FDA-approved dose. They compared outcomes in [48] . Eighty-six percent of the patients received a flat dosage of 1000 mg bid and the median starting dosage was 565 mg/m 2 bid, with a range of 305-1057 mg/m 2 . The median PFS for patients with measurable disease was 4.1 months (95 % CI 2.9-5.7) which was similar to the median PFS values 4.2-4.4 months for capecitabine monotherapy reported in the randomized trials with similar eligibility criteria [30, 31] . Although the authors did not report detailed toxicity outcomes, they stated that the low dose of capecitabine was well tolerated and only 2 patients discontinued capecitabine due to toxicity. In addition to the approach of lowering the starting capecitabine dose, alternative schedules have been investigated to improve treatment tolerability. Continuous metronomic capecitabine monotherapy has been tested in two phase II trials in patients with advanced breast cancer. Capecitabine was given continuously at 666 mg/m 2 bid in Harvey's trial and at fixed dose 1500 mg once a day in Fedele's trial [49, 50] . Overall response rate and median TTP/PFS was 36 % and 3.1 months in Harvey's trial and 24 % and 7 months in Fedele's trial, respectively. The most common grade 3-4 AE was hand foot syndrome (5-17 %) and in general these regimens were well tolerated. In Japan, an intermittent 4-week schedule (828 mg/m 2 bid, days 1-21 every 28 days) has been studied in phase II trials of advanced breast cancer [51] [52] [53] . In the trials, overall response rate and median TTP/PFS was 18-46 % and 5.1-7.2 months, respectively. These results are comparable to those with the standard 3-weekly intermittent schedule. An incidence of hand-foot syndrome (15-18 %) was similar to the 3-weekly regimen, but high grade diarrhea was seen in only one patient in these trials. Notably, a 7-days-on, 7-days-off (7/7) regimen of capecitabine was developed by Traina et al. based on the Norton-Simon mathematical model [54] . In their phase I trial, the most frequently grade 2-3 AEs were hand-foot syndrome (29 %), leukopenia/neutropenia (24 %), and fatigue (19 %). The maximum-tolerated doses of capecitabine was 2000 mg bid. Although capecitabine monotherapy on this 7/7 schedule has not been evaluated in larger clinical trials, this dosing schedule is commonly used in the U.S. because of its good tolerability seen in daily practice.
As treatment for metastatic breast cancer is palliative, minimizing toxicity and loss of function associated with treatment is of major importance. Improvement in chemotherapy tolerability without compromising efficacy is of particular importance in older adults with MBC. Elderly cancer patients are known to be at higher risk of chemotherapy-related adverse events [55, 56] . In a pooled analysis of five phase II/III trials of capecitabine 1250 mg/ m 2 /day bid (14/21), an incidence of treatment discontinuation due to toxicity was higher in women [65 years (24.4 %) compared with younger women (13.0-15.0 %) [3] . Additionally, treatment-related mortality was observed in a phase 2 study of capecitabine monotherapy in the older (C65 years) adults with MBC [15] . In this trial two of 30 patients treated with capecitabine starting dose of 1250 mg/m 2 bid and one of 43 patients treated with a lower starting dose (1000 mg/m 2 ) died due to toxicities. Given these findings, a prospective study of low dose capecitabine monotherapy (e.g., fixed-dose 1000 mg bid, 2 weeks on and 1 week off) in this population may be indicated in order to not only better assess the survival outcomes but also toxicity and outcomes particularly important for the elderly such as the maintenance of independent physical and social function, and quality of life.
Our study had several limitations. First, significant heterogeneity was observed in the incidence analyses although we included only phase II and III trials of breast cancer patients. This may be related to the differences in treatment intent, line of therapy, prior treatments and sample size. We conducted all analyses using the randomeffects model to take into account the between-study variation. Second, this is a meta-analysis at study level; therefore variables at the patient level were not incorporated into the analysis. Thus we could not establish risk factors associated with the development of toxicities. Third, as with any meta-analysis, the results described here are affected by the limitations of individual clinical trials that were selected for this meta-analysis.
In conclusion, our meta-analysis showed that capecitabine monotherapy at 1000 mg/m 2 bid for 14 days every 21 days has a clinically meaningful and significantly better toxicity profile in patients with breast cancer compared to the approved dose of capecitabine at 1250 mg/m 2 bid. Given our finding and the efficacy results from the clinical trials, capecitabine monotherapy at 1000 mg/m 2 bid for 14 days every 21 days is a reasonable standard of care. Prospective studies are warranted to determine whether further lower doses of capecitabine or other doses and schedules can achieve improvement in tolerability without compromising efficacy in patients with advanced breast cancer.
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